% Opus 4 S36.VIS.01.P33
\begin{minipage}{\textwidth}
\vspace{-0.5cm}
\renewcommand{\arraystretch}{1.61} % Adjust row height for better readability
\setlength{\tabcolsep}{0pt} % Reduces horizontal padding inside table cells
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Log vs.\ Report vs.\ Model Charts: Prompt 41} \\
\vspace{0.055cm}
\midrule 
\raggedright
\vspace{0.05cm}
\fontsize{8.25pt}{10pt}\selectfont
\textbf{Prompt for Cross-Model Meta-Verification Analysis Visualizations} \\
\vspace{0.05cm}
You have been provided with 5 verification analysis outputs from different AI models (use these terms grk4, grk3, ops4, g25p, o3pr) that were all given the same prompt template to analyze three clinical trials for meta-verification consistency.\\
\vspace{0.05cm}
\textbf{Analysis Summary:} Provide a two-paragraph explanation of findings regarding the correspondence between the AI models' outputs. Focus on: patterns of agreement/disagreement between models in their meta-verification calculations, specific tables where models showed highest/lowest correspondence in Row Consistency Scores, systematic differences in statistical calculation approaches (mean, range, SD), and implications for AI model reliability in meta-analysis of clinical trial discrepancies. Cite visualizations 01-10 throughout the analysis summary.\\
\vspace{0.05cm}
Generate 10 separate visualizations in Python scripts (numbered 01-10) as follows:\\
\vspace{0.05cm}
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 1. \hspace{0.075cm} Heatmap showing Row Consistency Scores across all models (5 models x 6 tables) with annotations for exact values and color gradient from 8.0 to 10.0}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 2. \hspace{0.075cm} Grouped bar chart comparing Mean calculations for Table 2 (Baseline Characteristic Deviations) across all 5 models for each of the 5 baseline characteristics}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 3. \hspace{0.075cm} Scatter plot matrix showing pairwise model agreement for all Row Consistency Scores across the 6 tables, with correlation coefficients and regression lines}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 4. \hspace{0.075cm} Box plot displaying the distribution of Standard Deviation calculations across models for Table 3 (Median OS Difference) for all 5 arms}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 5. \hspace{0.075cm} Radar chart comparing each model's Row Consistency Scores for all 6 meta-verification tables, with separate traces for each model}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 6. \hspace{0.075cm} Line graph showing Range calculations across models for Table 6 (\raisebox{0.25ex}{\scalebox{0.7}{$\geq$}}G3 AE Rate Difference) for all 5 arms, with confidence intervals}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 7. \hspace{0.075cm} Parallel coordinates plot displaying how each model calculated statistics (Mean, Range, SD) for Table 4 (Median PFS Difference) across all arms}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 8. \hspace{0.075cm} Stacked bar chart showing the frequency of exact agreement (difference < 0.01), minor discrepancies (0.01-0.1), and major discrepancies (>0.1) between model pairs for all calculated values}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 9. \hspace{0.075cm} Bubble chart plotting Mean vs. SD calculations for Table 5 (12-Month OS Rate Difference) by arm, with bubble size representing Range and color representing model}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.1em \hangafter=1 \hspace{0.4cm} 10. Diverging bar chart highlighting the largest positive and negative deviations from the median Row Consistency Score for each table across all models, sorted by magnitude of deviation}\\
"Begin grk4 = Grok 4"  "End grk4 = Grok 4" "Begin grk3 = Grok 3 Think"  "End grk3 = Grok 3 Think" "Begin ops4 = Opus 4 Extended"  "End ops4 = Opus 4 Extended" "Begin g25p = Gemini 2.5 Pro"  "End g25p = Gemini 2.5 Pro" "Begin o3pr = ChatGPT o3-pro" "End o3pr = ChatGPT o3-pro" \\
\vspace{0.05cm}
\lbrack S50.TST.01.P40\rbrack \hspace{0.025cm} \lbrack S51.TST.02.P40\rbrack \hspace{0.025cm} \lbrack S52.TST.03.P40\rbrack \hspace{0.025cm} \lbrack S53.TST.04.P40\rbrack \hspace{0.025cm} \lbrack S54.TST.05.P40\rbrack  \\
\end{tabular}
\vspace{-0.4cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S55.VIS.01.P41}
\bottomrule
\label{PromptLRMC}
\end{table}


\vspace{-0.2cm}


\renewcommand{\arraystretch}{1.61} % Adjust row height for better readability
\setlength{\tabcolsep}{0pt} % Reduces horizontal padding inside table cells
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Log vs.\ Report vs.\ Trial Charts: Prompt 42} \\
\vspace{0.055cm}
\midrule 
\raggedright
\vspace{0.05cm}
\fontsize{8.25pt}{10pt}\selectfont
\textbf{Prompt for Meta-Verification Cross-Trial Consistency Analysis} \\
\vspace{0.05cm}
You have been provided with 5 meta-verification analysis outputs from different AI models (grk4, grk3, ops4, g25p, o3pr) that independently analyzed the consistency of discrepancies, deviations, and differences across three clinical trials. Each model calculated meta-verification consistency scores using standardized formulas across six key comparison dimensions: cohort distribution, baseline characteristics, median OS differences, median PFS differences, 12-month OS rate differences, and grade \raisebox{0.25ex}{\scalebox{0.7}{$\geq$}}3 adverse event rate differences.\\
\vspace{0.05cm}
\textbf{Analysis Summary:} Provide a two-paragraph explanation synthesizing the collective findings regarding the meta-verification consistency patterns identified across all five models. Focus on: the overall consistency patterns in measurement discrepancies across trials, specific meta-verification tables showing highest/lowest row consistency scores, the relationship between baseline deviation consistency and outcome difference consistency, and implications for understanding systematic vs. random sources of variation in trial reporting. Include statistical measures (mean row consistency scores ranging from 8.8-10.0, coefficient of variation across models, inter-model agreement metrics, and Spearman's rank correlations between different meta-verification dimensions where applicable). Focus less on direct comparisons between the 5 analyses. Cite visualizations 01-10 throughout the analysis summary.\\
\vspace{0.05cm}
Generate 10 separate visualizations in Python scripts (numbered 01-10) as follows:\\
\vspace{0.05cm}
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 1. \hspace{0.075cm} Heatmap showing the consensus Row Consistency Scores (averaged across all 5 models) for all 6 meta-verification tables, with cells color-coded by score magnitude (8.0-10.0 scale) and annotated with inter-model standard deviations}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 2. \hspace{0.075cm} Box plot displaying the distribution of row consistency scores by meta-verification category (Cohort vs. Baseline vs. OS Difference vs. PFS Difference vs. 12-Month OS Rate vs. AE Rate), revealing patterns in measurement consistency}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 3. \hspace{0.075cm} Scatter plot matrix showing pairwise relationships between consistency scores from different meta-verification tables, with regression lines and R² values for each pair}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 4. \hspace{0.075cm} Radar chart comparing the consistency profile of each treatment arm (A-E) across all meta-verification dimensions, showing arm-specific measurement reliability patterns}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 5. \hspace{0.075cm} Line graph with error bars showing how mean cell statistics (Mean, Range, SD) vary across treatment arms for each meta-verification table, with separate panels for each table}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 6. \hspace{0.075cm} Clustered heatmap showing the correlation structure between all row consistency scores and their underlying cell statistics (means, ranges, SDs), with dendrogram showing hierarchical relationships}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 7. \hspace{0.075cm} Violin plot comparing the distribution of consistency scores between Formula A metrics (standard) vs. Formula B metrics (percentage-based), overlaid with individual data points}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 8. \hspace{0.075cm} 3D surface plot showing the relationship between overall mean values, overall SD values, and resulting consistency scores across all metrics, illustrating the scoring formula landscapes}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 9. \hspace{0.075cm} Sankey diagram showing the flow from raw trial discrepancy values through cell statistics (Mean, Range, SD) to final row consistency scores for each meta-verification table}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.25em \hangafter=1 \hspace{0.4cm} 10. Ridge plot (joy plot) showing the distribution of individual trial values that contribute to each meta-verification table's consistency scores, stacked by table type and colored by consistency score magnitude}\\
"Begin grk4 = Grok 4" "End grk4 = Grok 4" "Begin grk3 = Grok 3 Think" "End grk3 = Grok 3 Think" "Begin ops4 = Opus 4 Extended" "End ops4 = Opus 4 Extended" "Begin g25p = Gemini 2.5 Pro" "End g25p = Gemini 2.5 Pro" "Begin o3pr = ChatGPT o3-pro" "End o3pr = ChatGPT o3-pro" \\
\vspace{0.05cm}
\lbrack S50.TST.01.P40\rbrack \hspace{0.025cm} \lbrack S51.TST.02.P40\rbrack \hspace{0.025cm} \lbrack S52.TST.03.P40\rbrack \hspace{0.025cm} \lbrack S53.TST.04.P40\rbrack \hspace{0.025cm} \lbrack S54.TST.05.P40\rbrack  \\
\end{tabular}
\vspace{-0.4cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S56.VIS.02.P42}
\bottomrule
\label{PromptLRTC}
\end{table}
\end{minipage}







\begin{minipage}{\textwidth}
\vspace{-0.5cm}
\renewcommand{\arraystretch}{1.71}
\setlength{\tabcolsep}{0pt}
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{In Silico Trial Overview: Prompt 43} \\
\vspace{0.055cm}
\midrule 
\raggedright
\fontsize{7.5pt}{8.75pt}\selectfont
“Instructions Start” \\
\vspace{0.05}
Analyze, utilize, and cite the provided documents to produce a comprehensive virtual study overview of the completed 100,000-patient virtual triplicate simulations. Produce a single, detailed report in the “Executive Summary”, “Technical Details”, “Key Insights” format. Use large, interpretable markdown tables designated with appropriate rows R1, R2.. and columns C1, C2.. suitable for downstream data extraction and visualization. \\
\vspace{0.05cm}
\textbf{Input Files for Processing:}\\
\parbox[t]{17.25cm}{\raggedright \hangindent=3.6em \hangafter=1 \hspace{0.4cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.1cm} Trial reports, log file verifications, external validations, and visualizations for a 100,000-patient, 5-arm in-silico Phase III simulation run in triplicate and verified by multiple AI models (grk4, grk3, ops4, g25p, o3pr). Log file verfications correspond to files such as S35.VER.02.P32.} \\
\vspace{0.1cm}
\footnotesize \textbf{A. Virtual Study Triplicate Details} \fontsize{7.5pt}{8.75pt}\selectfont \\
\hspace{0.45cm} 1. \textbf{Four Tables with specific rows R1, R2.. and columns C1, C2..}\\ 
\hspace{0.45cm} 2. \textbf{Fill in Details of each cell with combined data from the included files below} \\
\hspace{0.45cm} 3. \textbf{Table 01: 3 Virtual Trials - Provide Additional Details} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Study Title/Identifier}} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Primary Goal}} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Trial Phase Equivalence} (Phase III details)} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Study Design} (5-arm in-silico simulation)} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Trial Arms} (List the specific arms for each)} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Patient Population Size}} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Patient Archetypes} (7 archetypes)} \\
\hspace{0.45cm} 4. \textbf{Table 02: 3 Virtual Trial Details - Provide Additional Details} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Drug Combination(s)} (Note the shared core triplet)} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Patient Data Granularity} (Describe the level of detail for virtual patient creation)} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Modeling Architecture} (100K trial's exponential survival model)} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Project Timeline}} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Primary Endpoints}} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=4.8em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Key AI Models Utilized} (List for both, based on the provided information)} \\
\hspace{0.45cm} 5. \textbf{Table 03: Benefits and Drawbackss - Provide Additional Details} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=6.5em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Itemized Benefits} of the Completed 100K Patient Triplicate Simulation:
Pay particular attention to all benefits derived from the completed triplicate simulation. Analyze the value of its speed, scale, and robust cross-model/cross-trial verification (as seen in files such as S43, S48, S49, S50, S55, S56).} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=6.5em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Itemized Drawbacks} of the Completed 100K Patient Triplicate Simulation:
List the drawbacks and limitations of the 100K trial's approach, considering factors like its simplified patient models and potential for "black-box" objections. Detail how methods used for the simulated trials could be improved in future studies.} \\
\hspace{0.45cm} 6. \textbf{Table 04: Reproducibility Findings - Most Comprehensively Detailed Table} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=6.5em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Validation} (100K trial's internal log verification and external validation against Flatiron data) Provide full detail regarding all results reported. Be sure to include inclusion of data synergies from Table T1 - OS concordance, Table T2 - OS Summary Metrics, and Table T3-ECOG Confidence scores.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=6.5em \hangafter=1 \hspace{0.7cm} \hspace{0.45cm} \raisebox{-0.5ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.15cm} \textbf{Reproducibility} (Overall reproducibility metrics of triplicate runs and cross-model verification in files like S43, S50, S55, S56). Include analysis of visualization scripts in Python from files like S48.VIS.01.P38. Be sure to include in full detail how reproducibility across the three simulated trials was observed or not observed by analyzing, utilizing, and citing specific documents included below.} \\
“Instructions End” \\
“Use Model Abbreviations in Output Start” \\
grk4 = Grok 4, grk3 = Grok 3, ops4 = Opus 4, g25p = Gemini 2.5 Pro, o3pr = ChatGPT o3-pro, o3ph = ChatGPT o3-pro Research \\
“Use Model Abbreviations in Output End” \\
”File Descriptions Start” \\
S33.TRL.13.P30 = Trial 1 (Example) \\
S35.VER.02.P32 = Trial 1 tables vs. log file verifications (Example) \\
S35b.VER.03.P34 = Trial 1 external validation of log file (Example) \\
S36.VIS.01.P33 = Trial 1 visualizations (Example) \\
S37.TRL.14.P30 = Trial 2  \\
S38.VER.01.P32 = Trial 2 tables vs. log file verifications \\
S38b.VER.02.P35 = Trial 2 external validation of log file \\
S39.VIS.01.P33 = Trial 2 visualizations \\
S40.TRL.15.P30 = Trial 3 \\
S41.VER.01.P32 = Trial 3 tables vs. log file verifications \\
S41b.VER.02.P36 = Trial 3 external validation of log file \\
S42.VIS.01.P33 = Trial 3 visualizations \\
S43.TST.01.P37 = grk4 3 Trial Tables Cross-Verification of Dataset 2 (cross-trial verification, 5 table output) (Example) \\
S44.TST.02.P37 = grk3 3 Trial Tables Cross-Verification of Dataset 2 (cross-trial verification, 5 table output)   \\
S45.TST.03.P37 = ops4 3 Trial Tables Cross-Verification of Dataset 2 (cross-trial verification, 5 table output)   \\
S46.TST.04.P37 = g25p 3 Trial Tables Cross-Verification of Dataset 2 (cross-trial verification, 5 table output)  \\
S47.TST.05.P37 = o3pr 3 Trial Tables Cross-Verification of Dataset 2 (cross-trial verification, 5 table output)  \\
S48.VIS.01.P38 = 3 Trial Tables Cross-Verification: Visualize Models (Example) \\
S49.VIS.02.P39 = 3 Trial Tables Cross-Verification: Visualize Trials (Example) \\
S50.TST.01.P40 = grk4 Meta-Verification Tables Cross-Trial of Dataset 3  \\S35.VER.02.P32, S38.VER.01.P32, S41.VER.01.P32 (3 report tables vs. log (S Files) vs. 3 trials. 6 table output) (Example) \\
S51.TST.02.P40 = grk3 Meta-Verification Tables Cross-Trial of Dataset 3  \\S35.VER.02.P32, S38.VER.01.P32, S41.VER.01.P32 (3 report tables vs. log  (S Files) vs. 3 trials. 6 table output) \\
S52.TST.03.P40 = ops4 Meta-Verification Tables Cross-Trial of Dataset 3  \\S35.VER.02.P32, S38.VER.01.P32, S41.VER.01.P32 (3 report tables vs. log (S Files) vs. 3 trials. 6 table output) \\
S53.TST.04.P40 = g25p Meta-Verification Tables Cross-Trial of Dataset 3  \\S35.VER.02.P32, S38.VER.01.P32, S41.VER.01.P32 (3 report tables vs. log (S Files) vs. 3 trials. 6 table output)\\
S54.TST.05.P40 = o3pr Meta-Verification Tables Cross-Trial of Dataset 3  \\S35.VER.02.P32, S38.VER.01.P32, S41.VER.01.P32 (3 report tables vs. log (S Files) vs. 3 trials. 6 table output) \\
S55.VIS.01.P41 = Verification Tables Cross-Trial: Visualize Models (Example) \\
S56.VIS.02.P42 = Verification Tables Cross-Trial: Visualize Trials (Example)
”File Descriptions End” \\
\vspace{0.05cm}
\noindent
[S33.TRL.13.P30] [S35.VER.02.P32] [S35b.VER.03.P34] [S36.VIS.01.P33] [S37.TRL.14.P30] [S38.VER.01.P32] [S38b.VER.02.P35] [S39.VIS.01.P33] [S40.TRL.15.P30] [S41.VER.01.P32] [S41b.VER.02.P36] [S42.VIS.01.P33] [S43.TST.01.P37] [S44.TST.02.P37] [S45.TST.03.P37] [S46.TST.04.P37] [S47.TST.05.P37] [S48.VIS.01.P38] [S49.VIS.02.P39] [S50.TST.01.P40] [S51.TST.02.P40] [S52.TST.03.P40] [S53.TST.04.P40] [S54.TST.05.P40] [S55.VIS.01.P41] [S56.VIS.02.P42]\\
\end{tabular}
\vspace{-0.4cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S57.REP.01.P43}
\bottomrule
\label{PromptISTO}
\end{table}
\end{minipage}










\begin{minipage}{\textwidth}
\renewcommand{\arraystretch}{1.61} % Adjust row height for better readability
\setlength{\tabcolsep}{0pt} % Reduces horizontal padding inside table cells
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Trial Overview Charts: Prompt 43b1} \\
\vspace{0.055cm}
\midrule 
\raggedright
\vspace{0.05cm}
\fontsize{9pt}{10.5pt}\selectfont
Based on the included comprehensive analysis of the 100,000-patient triplicate simulation study evaluating novel therapies for advanced Pancreatic Ductal Adenocarcinoma (PDAC), please generate 10 separate visualization scripts in Python that effectively communicate the key clinical findings, validation results, and methodological insights from this virtual trial. The visualizations should help stakeholders understand the efficacy-toxicity trade-offs, biomarker importance, and robustness of the simulation methodology.\\
\vspace{0.1cm}
Please create the following visualizations using Python:\\
\vspace{0.1cm}
01) Kaplan-Meier Survival Curves: Display overall survival curves for all 5 treatment arms with median OS values and confidence intervals annotated\\
02) Forest Plot of Hazard Ratios: Show OS and PFS hazard ratios with 95\% CIs for Arms A-D versus control Arm E to visualize treatment effects\\
03) Stacked Bar Chart of Adverse Events: Compare Grade 3+ adverse event rates across all 5 arms highlighting the efficacy-toxicity trade-off\\
04) Heatmap of Archetype-Specific Outcomes: Display median OS across 7 patient archetypes and 5 treatment arms to identify subgroup benefits\\
05) Radar Chart of External Validation: Compare simulated control arm metrics against Flatiron real-world data for OS\% at multiple timepoints and ECOG distribution\\
06) Box Plot of Cross-Trial Reproducibility: Show the distribution of key metrics across the three simulation runs demonstrating consistency\\
07) Waterfall Plot of KRAS G12C Response: Illustrate the differential treatment benefit for KRAS G12C patients across arms containing versus not containing Daraxonrasib\\
08) Scatter Plot Matrix of AI Model Agreement: Display pairwise correlations between the 5 AI models' consistency scores with clustering patterns\\
09) Sankey Diagram of Patient Flow: Visualize patient allocation across arms and progression through key clinical milestones including death and progression events\\
10) Combined Efficacy-Safety Bubble Plot: Plot median OS versus Grade 3+ AE rates for all arms with bubble size representing patient numbers to aid treatment selection decisions.\\
“Start Report”  “End Report”\\
\vspace{0.05cm}
\lbrack S57.REP.01.P43\rbrack  \\
\end{tabular}
\vspace{-0.4cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S57b.VIS.01.P43b}
\bottomrule
\label{PromptTROC1}
\end{table}



\renewcommand{\arraystretch}{1.61} % Adjust row height for better readability
\setlength{\tabcolsep}{0pt} % Reduces horizontal padding inside table cells
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Trial Overview Charts: Prompt 43b2} \\
\vspace{0.055cm}
\midrule 
\raggedright
\vspace{0.05cm}
\fontsize{9pt}{10.5pt}\selectfont
Based on the included comprehensive analysis of the 100,000-patient triplicate simulation study evaluating novel therapies for advanced Pancreatic Ductal Adenocarcinoma (PDAC), please generate 10 separate visualization scripts in Python that effectively communicate the key clinical findings, validation results, and methodological insights from this virtual trial. The visualizations should help stakeholders understand the efficacy-toxicity trade-offs, biomarker importance, and robustness of the simulation methodology.\\
\vspace{0.1cm}
Please create the following visualizations using Python:\\
\vspace{0.1cm}
01) Kaplan-Meier Survival Curves: Display overall survival curves for all 5 treatment arms with median OS values and confidence intervals annotated\\
02) Forest Plot of Hazard Ratios: Show OS and PFS hazard ratios with 95\% CIs for Arms A-D versus control Arm E to visualize treatment effects\\
03) Stacked Bar Chart of Adverse Events: Compare Grade 3+ adverse event rates across all 5 arms highlighting the efficacy-toxicity trade-off\\
04) Heatmap of Archetype-Specific Outcomes: Display median OS across 7 patient archetypes and 5 treatment arms to identify subgroup benefits\\
05) Radar Chart of External Validation: Compare simulated control arm metrics against Flatiron real-world data for OS\% at multiple timepoints and ECOG distribution\\
06) Box Plot of Cross-Trial Reproducibility: Show the distribution of key metrics across the three simulation runs demonstrating consistency\\
07) Waterfall Plot of KRAS G12C Response: Illustrate the differential treatment benefit for KRAS G12C patients across arms containing versus not containing Daraxonrasib\\
08) Scatter Plot Matrix of AI Model Agreement: Display pairwise correlations between the 5 AI models' consistency scores with clustering patterns\\
09) Sankey Diagram of Patient Flow: Visualize patient allocation across arms and progression through key clinical milestones including death and progression events\\
10) Combined Efficacy-Safety Bubble Plot: Plot median OS versus Grade 3+ AE rates for all arms with bubble size representing patient numbers to aid treatment selection decisions.\\
“Start Report”  “End Report”\\
\vspace{0.05cm}
\lbrack S57.REP.01.P43\rbrack  \\
\end{tabular}
\vspace{-0.4cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S57b.VIS.01.P43b}
\bottomrule
\label{PromptTROC2}
\end{table}
\end{minipage}









\begin{minipage}{\textwidth}
\vspace{-0.5cm}
\renewcommand{\arraystretch}{1.61}
\setlength{\tabcolsep}{0pt}
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Meta-Analysis: Prompt 44 (I/III)} \\
\vspace{0.055cm}
\midrule
\raggedright
\fontsize{9pt}{10.5pt}\selectfont

Produce a complete, audit-ready "Comparative Clinical Metrics Meta-Analysis of the 100,000-Patient Virtual Trial Triplicate" as described in the provided report against other publicly available in-silico and real-world clinical trials in advanced Pancreatic Ductal Adenocarcinoma (PDAC) from 2010-2025. The primary focus of this analysis is a rigorous comparison of clinical trial metrics, designed to produce data and tables suitable for advanced downstream data visualization. \\

Use large, interpretable markdown tables designated with the strict R1, R2.. and C1, C2.. format for all tables. The primary data source for the 100,000-patient trial triplicate is exclusively the provided "Start Report" text. All quantitative data for external studies must be traceable via a direct URL. For any metric not explicitly stated in a source, state 'N/R' (Not Reported). \\

Return a single output containing the sections in this order: \\

\textbf{Abstract} (structured, $\leq$300 words) \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Background:} Briefly state the challenges of traditional PDAC clinical trials and the emergence of in-silico trials as a tool for hypothesis generation and trial optimization.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Objective:} To conduct a systematic meta-analysis comparing the clinical efficacy, safety, and methodological parameters of the 100K-patient virtual trial (from the provided report) against other published in-silico and real-world interventional PDAC trials.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Methods:} Outline the data sources (provided report, PubMed, ClinicalTrials.gov), search strategy, study selection criteria (PRISMA), and the main data points for comparison (OS, PFS, AE rates, subgroup effects). Mention the development of a quantitative Efficacy-Toxicity Score (ETS) for head-to-head comparison.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Results:} Summarize the key comparative findings, including the relative performance of the virtual triplet arm (Arm A), the identification of concordance and discordance (e.g., ECOG mismatch), and the outcome of the head-to-head ETS scoring.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Conclusions:} State the main conclusions regarding the clinical utility and methodological standing of the 100K-patient simulation in the context of other PDAC research.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Registration:} PROSPERO Registration Number: [Placeholder]} \\

\textbf{Plain-language summary} ($\leq$250 words) \\
Provide a clear, non-technical summary explaining what virtual clinical trials are, how the 100,000-patient simulation was compared to other computer-based and real-patient trials for pancreatic cancer, and what the main takeaways are for researchers designing future cancer studies. \\

\textbf{Background} \\
Briefly describe the high failure rates, long timelines, and significant costs associated with traditional oncology clinical trials, specifically in a challenging disease like PDAC. Introduce in-silico (computer-simulated) clinical trials as an emerging methodology to de-risk, accelerate, and optimize drug development. State that this meta-analysis will contextualize a large-scale virtual trial within the existing landscape of both virtual and real-world research. \\

\textbf{Objectives} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} The primary objective is to systematically compare the clinical trial metrics (efficacy, safety, patient characteristics, and outcomes) of the 100,000-patient virtual trial triplicate (as detailed in the provided report) against:} \\
\hspace{1.2cm} 1. Other publicly available in-silico PDAC trials. \\
\hspace{1.2cm} 2. Pivotal real-world interventional Phase II and Phase III PDAC clinical trials. (Always prefer Phase III trials). \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} The secondary objective is to develop and apply a quantitative scoring model to facilitate a direct head-to-head comparison of the therapeutic regimens across different study types and to identify key research gaps for future in-silico modeling.} \\

\textbf{Methods} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Data Sources:} The primary data for the 100K-patient triplicate simulation will be extracted exclusively from the provided "Start Report" text. External data for comparator studies will be sourced from PubMed, ClinicalTrials.gov, ASCO/ESMO meeting abstracts, and peer-reviewed literature published between January 1, 2010, and December 31, 2025.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Search Strategy:} Specify the search terms used for external studies (e.g., "pancreatic adenocarcinoma," "PDAC," "in-silico," "virtual trial," "computational model," "Phase III," "Phase II," "Overall Survival"). State that the search is limited to English-language publications.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Study Selection:} Provide a PRISMA flow count in a table format.} \\

{\renewcommand{\arraystretch}{1.05}
\begin{tabular}{ll}
R \vspace{0.1cm} & C1: Stage \hspace{6.6cm} C2: Count \\
R1 \vspace{0.1cm}& Records identified from databases \hspace{3.55cm} [Number] \\
R2 \vspace{0.1cm}& Records removed before screening (e.g., duplicates) \hspace{1.27cm} [Number] \\
R3 \vspace{0.1cm}& Records screened \hspace{5.64cm} [Number] \\
R4 \vspace{0.1cm}& Records excluded \hspace{5.6cm} [Number] \\
R5 \vspace{0.1cm}& Reports sought for retrieval \hspace{4.4cm} [Number] \\
R6 \vspace{0.1cm}& Reports not retrieved \hspace{5.2cm} [Number] \\
R7 \vspace{0.1cm}& Reports assessed for eligibility \hspace{4.0cm} [Number] \\
R8 \vspace{0.1cm}& Reports excluded (with reasons) \hspace{3.8cm} [Number] \\
R9 \vspace{0.1cm}& Studies included in qualitative synthesis \hspace{2.8cm} [Number] \\
R10 \vspace{0.1cm}& Studies included in quantitative synthesis \hspace{2.65cm} [Number] \\
\end{tabular}}

\textbf{A. Virtual Study Comparison to Existing In-Silico PDAC Trials} \\

\textbf{Table 1: Comparative Clinical and Methodological Metrics of In-Silico PDAC Trials} \\
\textit{Instructions:} Populate this table by extracting data for C2 and C3 directly and exclusively from the provided "Start Report". Every cell for C2 and C3 must be filled; do not leave any as [Value from analysis of report]. For C4 and C5, find and cite credible published in-silico PDAC studies. \textbf{Prioritize selecting comparator studies that, at a minimum, report N, OS (or survival endpoint), and modeling architecture to ensure a meaningful comparison.} If a metric is not reported (N/R) in the external study, state that clearly. \\

\end{tabular}
\vspace{-0.4cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S58.REP.02.P44}
\bottomrule
\label{PromptMAI}
\end{table}
\end{minipage}









 

\begin{minipage}{\textwidth}
\vspace{-0.5cm}
\renewcommand{\arraystretch}{1.61}
\setlength{\tabcolsep}{0pt}
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Meta-Analysis: Prompt 44 (II/III)} \\
\vspace{0.055cm}
\midrule
\raggedright
\fontsize{9pt}{10.5pt}\selectfont

{\renewcommand{\arraystretch}{1.05}
\begin{tabular}{p{1cm} p{4cm} p{3.5cm} p{3.5cm} p{3cm} p{3cm}}
R & C1: Metric / Parameter & C2: 100K Triplicate & C3: 100K Triplicate & C4: Comparator & C5: Comparator \\
 & & (Control Arm E) & (Triplet Arm A) & In-Silico Study 1 & In-Silico Study 2 \\
R1 & Patient Population Size (N) & 20,000 & 20,000 & [Value] & [Value] \\
R2 & Patient Profile Summary & Fitter profile; ECOG & Fitter profile; ECOG & [Brief & [Brief \\
 & & 0/1/2 mismatch vs. RWD & 0/1/2 mismatch vs. RWD & Description] & Description] \\
R3 & Modeling Architecture & Exponential survival & Exponential survival & [e.g., Agent-Based, & [e.g., Agent-Based, \\
 & & model (Weibull k=1.0) & model (Weibull k=1.0) & QSP, PK/PD] & QSP, PK/PD] \\
R4 & Median Overall Survival (OS) & 6.1 months & 8.7 months & [Value] & [Value] \\
R5 & OS Hazard Ratio (HR vs. Control) & 1.00 (Reference) & $\sim$0.69 & [Value or N/R] & [Value or N/R] \\
R6 & Median Progression-Free & 3.1 months & N/R & [Value or N/R] & [Value or N/R] \\
 & Survival (PFS) & & & & \\
R7 & PFS Hazard Ratio (HR vs. Control) & 1.00 (Reference) & N/R & [Value or N/R] & [Value or N/R] \\
R8 & Grade $\geq$3 Adverse Events (\%) & 76.5\% & 94.0\% & [Value or N/R] & [Value or N/R] \\
R9 & Defined Patient Archetypes & 7 Archetypes & 7 Archetypes & [List or describe, & [List or describe, \\
 & & (ARCH-01 to ARCH-07) & (ARCH-01 to ARCH-07) & or N/R] & or N/R] \\
R10 & Key Subgroup Finding & N/A (Control) & Enhanced benefit in & [Describe key & [Describe key \\
 & & & ARCH-05 (KRAS G12C) & finding or N/R] & finding or N/R] \\
R11 & Source (URL / Report) & Source: Report & Source: Report & [URL to publication] & [URL to publication] \\
\end{tabular}}
\vspace{0.1cm}\\
\textbf{B. Virtual Study Comparison to Real-World In-Person PDAC Trials} \\

\textbf{Table 2: Comparative Clinical Metrics of Virtual vs. Real-World PDAC Trials} \\
\textit{Instructions:} Populate this table using the report for C2 and C3. For C4, C5, and C6, use data from well-known, pivotal Phase III and Phase II PDAC trials (e.g., MPACT, NAPOLI-1, PRODIGE 24) and provide URLs. For any virtual arm metric not directly stated in the report (e.g., Arm D OS), calculate it if a clear basis (e.g., HR and baseline) is provided. State that the value is Calculated. If no basis exists (e.g., AE\% for Arm D), state N/R. \\

{\renewcommand{\arraystretch}{1.05}
\begin{tabular}{p{1cm} p{2.4cm} p{2.75cm} p{2.75cm} p{3cm} p{3cm} p{3cm}}
R & C1: Metric / & C2: 100K Triplicate & C3: 100K Triplicate & C4: Real-World Phase & C5: Real-World Phase & C6: Real-World Phase \\
 & Parameter & (Triplet Arm A) & (Doublet Arm D) & III (e.g., MPACT) & III (e.g., NAPOLI-1) & II or III (Specify) \\
R1 & Study / Regimen & Triplet & Doublet & Gemcitabine + & nal-IRI + & [Regimen \\
 & & (Dara+Mita+nal-IRI) & (Dara+Mita) & nab-Paclitaxel & 5-FU/LV & Name] \\
R2 & Patient Population & 20,000 & 20,000 & [Value, e.g., 861] & [Value, e.g., 417] & [Value] \\
 & Size (N) & & & & & \\
R3 & Baseline ECOG PS & $>$95\% (Failed & $>$95\% (Failed & [Value] & [Value] & [Value] \\
 & 0/1 (\%) & validation vs. RWD) & validation vs. RWD) & & & \\
R4 & Median Overall & 8.7 months & [Calculated Value & [Value, e.g., 8.5 mo] & [Value, e.g., 6.1 mo] & [Value] \\
 & Survival (OS) & & from HR $\sim$0.76] & & & \\
R5 & OS Hazard Ratio & $\sim$0.69 & $\sim$0.76 & [Value, e.g., 0.72] & [Value, e.g., 0.67] & [Value] \\
 & (HR vs. SoC) & & & & & \\
R6 & Median Progression- & N/R & N/R & [Value, e.g., 5.5 mo] & [Value, e.g., 3.1 mo] & [Value] \\
 & Free Survival & & & & & \\
R7 & PFS Hazard Ratio & N/R & N/R & [Value, e.g., 0.69] & [Value, e.g., 0.56] & [Value] \\
 & (HR vs. SoC) & & & & & \\
R8 & Grade $\geq$3 Adverse & 94.0\% & N/R & [Value, e.g., 84\%] & [Value, e.g., 79\%] & [Value] \\
 & Events (\%) & & & & & \\
R9 & Objective Response & N/R & N/R & [Value, e.g., 23\%] & [Value, e.g., 16\%] & [Value] \\
 & Rate (ORR) (\%) & & & & & \\
R10 & Source (URL / & Source: Report & Source: Report & [URL to publication] & [URL to publication] & [URL to \\
 & Report) & & & & & publication] \\
\end{tabular}}


\textbf{C. Quantitative Head-to-Head Comparison and Pooled Analysis} \\
\textit{Instructions:} Create a comprehensive "flat" table suitable for data processing and visualization. Pool the key metrics from all selected studies (virtual and real-world) into this single table. \textbf{Ensure each experimental arm has its corresponding control arm listed in the table to provide the baseline for delta ($\Delta$) calculations.} Then, calculate the Efficacy-Toxicity Score (ETS) for each experimental arm as defined below. \\

\hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Pooling and Scoring Instructions:} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=5.5em \hangafter=1 \hspace{1.2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} For each study, identify the experimental arm(s) and its corresponding control arm. The control arm data is used for calculating the benefit and score.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=5.5em \hangafter=1 \hspace{1.2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} Calculate the \textbf{Efficacy-Toxicity Score (ETS)}: The ETS provides a single value to compare the overall clinical utility of a regimen, balancing its survival benefit against its toxicity burden, relative to its own control.} \\
\end{tabular}
\vspace{-0.1cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S58.REP.02.P44}
\bottomrule
\label{PromptMAII}
\end{table}
\end{minipage}
















\begin{minipage}{\textwidth}
\vspace{-0.5cm}
\renewcommand{\arraystretch}{1.61}
\setlength{\tabcolsep}{0pt}
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Meta-Analysis: Prompt 44 (III/III)} \\
\vspace{0.055cm}
\midrule
\raggedright
\fontsize{9pt}{10.5pt}\selectfont

\hspace{1.2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} \textbf{ETS Formula:} ETS = (Normalized\_OS\_Benefit) - (Normalized\_AE\_Increase) \\
\parbox[t]{17.25cm}{\raggedright \hangindent=5.5em \hangafter=1 \hspace{1.2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} \textbf{Normalization Formula:} To make metrics comparable, normalize them on a scale from 0 to 1 based on the range observed across all included \textit{experimental arms}.} \\
\hspace{2cm} \raisebox{0.2ex}{{\fontsize{6pt}{8pt}\selectfont$\blacksquare$}} \hspace{0.1cm} Normalized\_OS\_Benefit = (OS\_Arm - OS\_Control) / (Max\_OS\_Benefit - Min\_OS\_Benefit) \\
\hspace{2cm} \raisebox{0.2ex}{{\fontsize{6pt}{8pt}\selectfont$\blacksquare$}} \hspace{0.1cm} Normalized\_AE\_Increase = (AE\_Arm - AE\_Control) / (Max\_AE\_Increase - Min\_AE\_Increase) \\
\parbox[t]{17.25cm}{\raggedright \hangindent=8.0em \hangafter=1 \hspace{2cm} \raisebox{0.2ex}{{\fontsize{6pt}{8pt}\selectfont$\blacksquare$}} \hspace{0.1cm} Where Max/Min\_OS\_Benefit and Max/Min\_AE\_Increase are the maximum and minimum differences observed between any experimental arm and its respective control \textit{across all studies in the analysis}.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Sample Calculation:} Provide a full, step-by-step calculation for the ETS of the "100K Triplicate (Triplet Arm A)". Show the intermediate values for OS\_Benefit, AE\_Increase, the Max/Min range values, Normalized\_OS\_Benefit, Normalized\_AE\_Increase, and the final ETS. \\
\textbf{Table 3: Pooled Clinical Metrics and Head-to-Head Scoring}} \\

{\renewcommand{\arraystretch}{1.05}
\begin{tabular}{p{0.6cm} p{1.5cm} p{1.8cm} p{1.6cm} p{0.7cm} p{1.9cm} p{1.9cm} p{1.9cm} p{1.9cm} p{1.5cm} p{2.1cm}}
% \hline
R & C1: Study ID & C2: Study Type & C3: Trial Arm & C4: N & C5: Median OS (mo) & C6: OS vs Control ($\Delta$ mo) & C7: Grade $\geq$3 AEs (\%) & C8: AEs vs Control ($\Delta$ \%) & C9: Source URL & C10: Calculated ETS \\
% \hline
R1 & 100K-Sim & Virtual & Triplet (Arm A) & 20000 & 8.7 & +2.6 & 94.0 & +17.5 & Report & [Calculated Value] \\
R2 & 100K-Sim & Virtual & Control (Arm E) & 20000 & 6.1 & 0.0 & 76.5 & 0.0 & Report & N/A \\
R3 & 100K-Sim & Virtual & Doublet (Arm D) & 20000 & [Calculated] & [Calc $\Delta$] & N/R & N/A & Report & N/A \\
R4 & MPACT & Real-World & Gem+Nab-P & [N] & 8.5 & [Calc $\Delta$ vs Gem] & 84.0 & [Calc $\Delta$ vs Gem] & [URL] & [Calculated Value] \\
R5 & MPACT & Real-World & Gemcitabine & [N] & 6.7 & 0.0 & [Value] & 0.0 & [URL] & N/A \\
R6 & [StudyID] & [Type] & [Arm Name] & [N] & [Value] & [Calc $\Delta$] & [Value] & [Calc $\Delta$] & [URL] & [Calculated Value] \\
R7 & ... & ... & ... & ... & ... & ... & ... & ... & ... & ... \\
% \hline
\end{tabular}
}

\textbf{Authors' conclusions} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.7em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Summary of Findings:} Synthesize the results from Tables 1, 2, and 3. Discuss the clinical implications. How does the virtual trial's triplet regimen (Arm A) compare to real-world standards of care like FOLFIRINOX or Gem+Nab-P when considering both efficacy and toxicity (as quantified by the ETS)? Highlight the promise (or lack thereof) of the virtual doublet (Arm D). Discuss the methodological concordance (e.g., OS) and discordance (e.g., ECOG profile) and its impact on the translatability of the virtual findings.} \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.7em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Key Research Gaps and Future Directions:} Based on the analysis, identify critical gaps in in-silico cancer modeling. Use the table below to structure these findings.} \\

\textbf{Table 4: Identified Research Gaps and Recommendations} \\

{\renewcommand{\arraystretch}{1.05}
\noindent \begin{tabular}{p{0.65cm}p{2.65cm}@{\hspace{0.25cm}}p{4.35cm}@{\hspace{0.25cm}} p{4.35cm} @{\hspace{0.25cm}}p{4.35cm}}
R & C1: Identified Gap / Limitation & C2: Evidence from Analysis & C3: Proposed Future Direction / Recommendation & C4: Potential Impact \\
R1 & Patient Profile Realism & The 100K-Sim's ECOG profile was significantly healthier than RWD from MPACT/NAPOLI-1. (Source: Report, Table 2) & Incorporate real-world data distributions (e.g., from Flatiron, COTA) into the virtual patient generation process. & Improves the generalizability and predictive accuracy of simulation outcomes for real-world populations. \\
R2 & Model Complexity and Dynamics & The exponential survival model in the 100K-Sim does not capture treatment discontinuation or dose modification. (Source: Report, Table 1) & Develop and validate more sophisticated models (e.g., agent-based models, QSP) that simulate patient journeys more mechanistically. & Enables prediction of not just if a patient responds, but how and why, and allows for testing adaptive trial designs. \\
R3 & Biomarker Granularity \& Implementation & The report notes a data discrepancy in KRAS definition (91\% vs 5\%), potentially mis-applying the drug effect. (Source: Report) & Future models must link specific drug effects to validated biomarkers with high precision and apply them only to the correct subgroup. & Increases the power of simulations to identify potent biomarker-drug combinations and inform patient selection strategies. \\
R4 & Standardization of In-Silico Reporting & Comparator in-silico studies report heterogeneous metrics, making direct comparison difficult. (Source: Table 1) & Advocate for standardized reporting guidelines for in-silico trials, analogous to CONSORT for RCTs. & Enhances transparency, reproducibility, and the ability to perform robust meta-analyses like this one. \\
\end{tabular}}

\textbf{Appendices} \\
\hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Full Electronic Search String:} Provide the exact search string used for PubMed/other databases. \\
\parbox[t]{17.25cm}{\raggedright \hangindent=2.7em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Data-Extraction CSV:} Provide a Markdown table formatted as a CSV file, containing the raw data used to generate Table 3. This ensures data is machine-readable for future visualizations.} \\

Generated csv \\
StudyID,StudyType,Phase,TrialArm,N,Median\_OS\_mo,OS\_HR\_vs\_SoC,Median\_PFS\_mo,PFS\_HR\_vs\_SoC,Grade3\_plus\_AE\_pct,URL \\
100K-Sim,Virtual,III-equiv,Triplet (Arm A),20000,8.7,$\sim$0.69,N/R,N/R,94.0,Source: Report \\
100K-Sim,Virtual,III-equiv,Control (Arm E),20000,6.1,1.00,3.1,1.00,76.5,Source: Report \\
\lbrack ...populate with all other arms and studies from the analysis...\rbrack \\
“Start Report” “End Report”\\
\lbrack S57.REP.01.P43\rbrack
\end{tabular}
\vspace{-0.1cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S58.REP.02.P44}
\bottomrule
\label{PromptMAIII}
\end{table}
\end{minipage}









\begin{minipage}{\textwidth}
\renewcommand{\arraystretch}{1.61} % Adjust row height for better readability
\setlength{\tabcolsep}{0pt} % Reduces horizontal padding inside table cells
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Meta-Analysis Charts: Prompt 44b} \\
\vspace{0.055cm}
\midrule 
\raggedright
\vspace{0.05cm}
\fontsize{9pt}{10.5pt}\selectfont
Based on the meta-analysis comparing the 100K-patient virtual PDAC trial with other virtual and real-world clinical trials, generate 10 visualizations with white backgrounds using 10 separate Python scripts that effectively communicate the following key comparisons and findings:\\
\vspace{0.1cm}
Create the following visualizations to highlight the critical insights from this comparative analysis:\\
\vspace{0.1cm}
01) Forest Plot: Display hazard ratios with 95\% confidence intervals for overall survival comparing all experimental arms (virtual Triplet, virtual Doublet, MPACT Gem+nab-P, NAPOLI-1, FOLFIRINOX) versus their respective controls, showing how the virtual trial outcomes align with real-world trials\\
02) Scatter Plot with Efficiency Frontier: Plot median overall survival (x-axis) versus Grade \raisebox{0.25ex}{\scalebox{0.7}{$\geq$}}3 adverse events percentage (y-axis) for all treatment arms, with point sizes proportional to sample size and an efficiency frontier curve showing optimal efficacy-toxicity balance\\
03) Grouped Bar Chart: Compare median overall survival months across all experimental arms grouped by study type (virtual vs real-world), with error bars and control arm baselines shown as horizontal reference lines\\
04) Waterfall Plot: Display the Efficacy-Toxicity Score (ETS) for each experimental regimen ranked from highest to lowest, with positive scores in green and negative in red to show which treatments offer favorable risk-benefit profiles\\
05) Stacked Bar Chart: Show the distribution of ECOG performance status (0, 1, 2) across different trials to highlight the patient population discrepancy between the virtual trial (>95\% ECOG 0-1) and real-world trials\\
06) Heatmap: Create a comparison matrix showing key metrics (OS benefit, PFS benefit, HR, Grade \raisebox{0.25ex}{\scalebox{0.7}{$\geq$}}3 AE increase, ETS) across all experimental arms with color intensity indicating magnitude of effect\\
07) Butterfly Plot: Display OS benefit (months gained) on the right and toxicity increase (\% Grade \raisebox{0.25ex}{\scalebox{0.7}{$\geq$}}3 AE increase) on the left for each experimental arm, creating a mirror effect to visualize the trade-offs\\
08) Radar Chart: Compare the virtual Triplet, virtual Doublet, and FOLFIRINOX across multiple dimensions (OS, PFS, toxicity, patient fitness, biomarker specificity) to show their relative strengths and weaknesses\\
09) Sankey Diagram: Illustrate patient flow from baseline characteristics through treatment arms to outcomes, showing how the KRAS G12C subgroup (Archetype-05) derives enhanced benefit from Daraxonrasib-containing regimens\\
10) Timeline Visualization: Create a horizontal timeline showing the evolution of PDAC treatment standards from 2010-2025, marking when each real trial was conducted and where the virtual trial fits in the therapeutic landscape with median OS values annotated.\\
\vspace{0.05cm}
“Start Meta-analysis”  “End Meta-analysis”\\
\vspace{0.05cm}
\lbrack S58.REP.02.P44\rbrack \\
\end{tabular}
\vspace{-0.4cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S58b.VIS.01.P44b}
\bottomrule
\label{PromptMACharts}
\end{table}
\end{minipage}






% P Here
\begin{minipage}{\textwidth}
\vspace{-0.5cm}
\renewcommand{\arraystretch}{1.61}
\setlength{\tabcolsep}{0pt}
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Financial Assessment: Prompt 45 (I/IV)} \\
\vspace{0.055cm}
\midrule
\raggedright
\fontsize{9.5pt}{10.75pt}\selectfont
\textbf{PROMPT FOR FINANCIAL IMPLICATIONS ASSESSMENT}\\

\parbox[t]{17.25cm}{\raggedright \textbf{Primary Instruction:} You are an AI model specializing in life sciences finance and bioinformatics. Your task is to generate a complete, investment-grade "Financial Assessment and Value Proposition of a 100,000-Patient Triplicate Virtual Trial for PDAC Drug Development." This report must be framed for a startup seeking grant funding.} \\

\parbox[t]{17.25cm}{\raggedright The analysis will focus on the financial and strategic value of the specific triplicate simulation methodology detailed in the provided reports (S57.REP.01.P43) compared to both alternative in-silico approaches and traditional in-person clinical trials. The clinical context will be drawn from the provided meta-analysis (S58.REP.02.P44).} \\

\parbox[t]{17.25cm}{\raggedright Your output must be a single, plain-text document suitable for Google Docs. Use large, interpretable markdown tables with the specified R1, R2... and C1, C2... format for all structured data. You must not draw any final conclusions. Your role is to present the data, calculations, and financial frameworks as instructed, allowing the reader (e.g., a grant committee) to draw their own conclusions.} \\

\textbf{I. Executive Summary (Structured, \raisebox{0.25ex}{\scalebox{0.7}{$\leq$}}350 words)} \\

\parbox[t]{17.25cm}{\raggedright Instruction: Generate a structured executive summary with the following sections:} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Purpose:} State the report's purpose is to financially assess a triplicate virtual trial methodology as a capital-efficient tool for de-risking PDAC drug development for a startup.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Methodology:} Briefly describe the comparison of the 100K patient triplicate trial's costs and projected value against industry benchmarks for single-run virtual trials and Phase II/III in-person trials, using metrics like Cost of Evidence, De-Risking Value, and potential ROI.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Key Financial Findings (Instructions):} Synthesize the core financial arguments. For example: "The triplicate simulation, costing approximately \$36,330 (Source: S57.REP.01.P43 costs), generated robust, verifiable evidence in 30 days. This represents a >99\% cost reduction and a 98\% timeline acceleration compared to a typical Phase III PDAC trial, which can exceed \$100M and 5 years." Mention the value of identifying the superior risk-profile of Arm D as a key financial insight.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Value Proposition for Funding:} Frame the core argument for grant funding. For example: "This methodology provides a low-cost, high-confidence platform for making go/no-go decisions, preserving capital and directing resources toward assets with the highest probability of success. The robust, verifiable nature of the triplicate run (Source: S57.REP.01.P43, Table 04) is a key differentiator that minimizes investment risk."} \\

\textbf{II. Background: The Economic Imperative for Innovation in Oncology Trials} \\

\parbox[t]{17.25cm}{\raggedright Instruction: Briefly describe the unsustainable economics of traditional oncology clinical trials, focusing on PDAC. Highlight the high cost, long duration, and >90\% failure rate of drugs entering clinical phases. Frame in-silico trials not just as a scientific tool, but as a crucial financial strategy for startups to maximize capital efficiency and attract investment by generating early, robust evidence.} \\

\textbf{III. Objectives} \\

\parbox[t]{17.25cm}{\raggedright Instruction: State the primary objectives of the financial assessment:} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=1.5em \hangafter=1 \hspace{0.4cm} 1. \hspace{0.0025cm} To quantify the direct and estimated costs of the 100K patient triplicate simulation.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=1.5em \hangafter=1 \hspace{0.4cm} 2. \hspace{0.0025cm} To analyze the specific financial value and justification for the triplicate methodology versus a single simulation run.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 3. \hspace{0.0025cm} To compare the "Cost of Evidence" from this virtual trial against estimated costs for other in-silico and traditional in-person PDAC trials.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 4. \hspace{0.0025cm} To model the potential Return on Investment (ROI) and Net Present Value (NPV) of using this methodology to de-risk a drug development program, providing a quantitative basis for a grant application.} \\
\textbf{IV. Methods for Financial Assessment}\\

\parbox[t]{17.25cm}{\raggedright Instruction: Detail the financial methodology.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Data Sources:} Primary financial data for the 100K patient triplicate simulation is extracted from S57.REP.01.P43. Clinical context and real-world trial outcomes are from S58.REP.02.P44. External financial benchmarks for comparator trials will be sourced from credible, citable industry reports and publications (e.g., from Tufts CSDD, BIO, Deloitte).} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=1.5em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Financial Metrics:} List the key financial metrics that will be calculated and compared:} \\

\hspace{2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} Total Project Cost (broken down into labor, compute, and third-party services) \\
\hspace{2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} Cost per Virtual Patient \\
\hspace{2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} Cost of Reproducibility (the marginal cost of the 2nd and 3rd runs) \\
\hspace{2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} Cost of Evidence (Total Cost / Key Actionable Insight) \\
\hspace{2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} Estimated Cost of Failure Avoidance \\
\hspace{2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} Burn Rate Reduction (Salaries and operational costs saved due to accelerated timeline) \\
\hspace{2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} Return on Investment (ROI) \\
\hspace{2cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont$\circ$}} \hspace{0.07cm} Net Present Value (NPV) of Accelerated Development \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.75em \hangafter=1 \hspace{0.4cm} \raisebox{-0.2ex}{{\fontsize{12pt}{12pt}\selectfont\textbullet}} \hspace{0.075cm} \textbf{Estimation Strategy:} State that when direct financial data for comparator trials is unavailable, estimates will be derived using established industry benchmarks. All assumptions, formulas, and sources for these estimates must be explicitly stated and justified. For example, labor costs for comparator virtual trials will be estimated based on reported team size, duration, and blended market-rate salaries for bioinformatics personnel.} \\

\textbf{V. Results} \\

\textbf{A. Cost-Benefit Analysis: Triplicate Simulation vs. Single-Run Virtual Trials} \\

\parbox[t]{17.25cm}{\raggedright Instruction: Present a detailed cost breakdown of the 100K patient triplicate trial and compare it to estimated costs for other hypothetical single-run virtual trials. The purpose is to highlight the startup's operational efficiency and justify the cost of the triplicate methodology.} \\

\end{tabular}
\vspace{-0.15cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S59.REP.03.P45}
\bottomrule
\label{PromptFAI}
\end{table}
\end{minipage}

\newpage

\begin{minipage}{\textwidth}
\vspace{-0.5cm}
\renewcommand{\arraystretch}{1.61}
\setlength{\tabcolsep}{0pt}
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Financial Assessment: Prompt 45 (II/IV)} \\
\vspace{0.055cm}
\midrule
\raggedright
\fontsize{9.5pt}{10.75pt}\selectfont

\textbf{Table 1: Financial \& Methodological Comparison of In-Silico Trial Methodologies} \\
C1: Metric\\
C2: 100K Patient Triplicate Simulation\\
C3: Estimated Single-Run Virtual Trial (Standard)\\
C4: Estimated Advanced Mechanistic Model (e.g., QSP)\\
R1\\
Total Project Cost (USD)\\
(Calculate from S57.REP.01.P43 data)\\
(Estimate based on industry averages)\\
(Estimate based on higher complexity)\\

R2\\
Researcher Labor Cost\\
(Calculate from S57.REP.01.P43 data)\\
(Estimate: e.g., 2 researchers x 3 months x \$120/hr)\\
(Estimate: e.g., 4 researchers x 6 months x \$150/hr)\\
R3\\
AI/Cloud Compute Cost\\
(Sum from S57.REP.01.P43 data: \$340)\\
(Estimate: e.g., \$1,000 - \$5,000)\\
(Estimate: e.g., \$20,000 - \$100,000+)\\
R4\\
Total Project Duration\\
30 days (Source: S58.REP.02.P44, Abstract)\\
(Estimate: 3-6 months)\\
(Estimate: 6-12 months)\\
R5\\
Cost of Reproducibility\\
(Calculate marginal cost of runs 2 \& 3, likely dominated by compute/API costs)\\
Not Applicable (single run)\\
Not Applicable (single run)\\
R6\\
Cost per Virtual Patient\\
(Calculate: Total Cost / 100,000 patients)\\
(Calculate: Estimated Cost / Typical N, e.g., 1,000)\\
(Calculate: Estimated Cost / Typical N, e.g., 100)\\
R7\\
Key Methodological Benefit\\
High-confidence, verifiable results via triplicate runs and multi-AI validation (Source: S57.REP.01.P43, Table 04)\\
Rapid hypothesis screening\\
Deep biological mechanism exploration\\
R8\\
Source of Data/Estimate\\
S57.REP.01.P43, S58.REP.02.P44\\
(Cite industry report URL for labor/compute estimates)\\
(Cite industry report or publication URL for QSP cost estimates)\\

\textbf{Sample Calculations for Section A:} \\
Instruction: Provide three fully-worked sample calculations to demonstrate the required methodology. \\

\parbox[t]{17.25cm}{\raggedright \textbf{Total Project Cost for 100K Triplicate:} Labor Cost (1 researcher * 60 hr/wk * 4 wk * \$150/hr) + AI/API Costs (} \\

\parbox[t]{17.25cm}{\raggedright \hspace{0.4cm} 1. \hspace{0.0025cm} \$260 + \$30 + \$20 + \$20. Show the full calculation.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 2. \hspace{0.0025cm} \textbf{Cost of Reproducibility:} Assuming labor was for the entire project, the marginal cost of the 2nd and 3rd runs is primarily the compute/API cost. Estimate this by assuming the initial run cost 1/3 of the total API cost, so the cost of reproducibility is (2/3) * \$330. Justify this assumption.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 3. \hspace{0.0025cm} \textbf{Estimated Labor Cost for Comparator (C4):} Based on a cited report that advanced QSP models require a team of 4 FTEs for 6 months, calculate the labor cost. (4 researchers * 24 weeks * 40 hr/wk * \$150/hr). State all assumptions clearly.} \\

\textbf{Rationale for Estimates:} \\
\parbox[t]{17.25cm}{\raggedright Instruction: Provide a paragraph justifying all assumptions made in Table 1 for columns C3 and C4. Cite sources for market-rate salaries, typical team sizes, and cloud computing costs for different types of in-silico projects.} \\

\textbf{B. Value Proposition: Capital Efficiency vs. Traditional In-Person Trials}//
\parbox[t]{17.25cm}{\raggedright Instruction: Frame the financial comparison against traditional trials as a clear value proposition for a startup. Focus on capital preservation and risk reduction.} \\

\end{tabular}
\vspace{-0.1cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S59.REP.03.P45}
\bottomrule
\label{PromptFAII}
\end{table}
\end{minipage}

\newpage

\begin{minipage}{\textwidth}
\vspace{-0.5cm}
\renewcommand{\arraystretch}{1.61}
\setlength{\tabcolsep}{0pt}
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Financial Assessment: Prompt 45 (III/IV)} \\
\vspace{0.055cm}
\midrule
\raggedright
\fontsize{9.5pt}{10.75pt}\selectfont

\textbf{Table 2: Capital Efficiency and De-Risking: Virtual Triplicate vs. In-Person PDAC Trials} \\
C1: Financial Metric\\
C2: 100K Patient Triplicate Simulation\\
C3: Typical Phase II PDAC Trial (Estimate)\\
C4: Typical Phase III PDAC Trial (Estimate)\\
R1\\
Total Estimated Budget (USD)\\
(Value from Table 1)\\
(Estimate, e.g., \$15M - \$25M)\\
(Estimate, e.g., \$80M - \$150M)\\
R2\\
Total Project Duration\\
30 days\\
(Estimate, e.g., 2 - 3 years)\\
(Estimate, e.g., 4 - 6 years)\\
R3\\
Cost per Patient (USD)\\
(Value from Table 1)\\
(Calculate: Budget / N, e.g., \$20M / 150 patients)\\
(Calculate: Budget / N, e.g., \$100M / 800 patients)\\
R4\\
Capital at Risk (for go/no-go decision)\\
(Total budget from R1)\\
(Full budget from R1)\\
(Full budget from R1)\\
R5\\
Time-to-Decision Value\\
Generates go/no-go evidence in 1 month, saving years of burn rate.\\
Requires years of investment before a clear signal emerges.\\
Requires the largest and longest investment for a definitive result.\\
R6\\
Key Actionable Insight\\
Identified superior risk-profile of Arm D; confirmed high toxicity of Arm A (Source: S58.REP.02.P44, Conclusions).\\
Typically tests one hypothesis (e.g., one new drug vs SoC).\\
Confirms efficacy/safety for registration, but at maximum cost.\\
R7\\
Source of Estimate\\
S57.REP.01.P43\\
(Cite source for Phase II costs, e.g., BIO/Tufts CSDD report URL)\\
(Cite source for Phase III costs, e.g., JAMA/DiMasi et al. URL)\\

\textbf{Sample Calculations for Section B:} \\
Instruction: Provide three fully-worked sample calculations. \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 1. \hspace{0.0025cm} \textbf{Cost of Failure Avoidance:} A key insight from the simulation was the extreme toxicity (94\% Grade \raisebox{0.25ex}{\scalebox{0.7}{$\geq$}}3 AEs) of the triplet (Arm A) (Source: S58.REP.02.P44, Table 2). Estimate the value of this finding by calculating the cost of a failed Phase II trial (\$20M) minus the cost of the simulation. This represents capital saved.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 2. \hspace{0.0025cm} \textbf{Burn Rate Reduction:} Assume a startup's monthly burn rate for a clinical team (e.g., 5 personnel + overhead) is \$100,000. Calculate the total savings from getting a decision signal in 1 month versus waiting 2 years for a Phase II trial to read out. (24 months * \$100,000/month) - Simulation Cost.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 3. \hspace{0.0025cm} \textbf{Cost per Patient Comparison:} Directly compare the "Cost per Virtual Patient" from Table 1, C2, R6 with the estimated "Cost per Real Patient" for a Phase III trial from Table 2, C4, R3. Express the difference as a percentage reduction.} \\


\textbf{Rationale for Estimates:} \\
\parbox[t]{17.25cm}{\raggedright Instruction: Provide a detailed paragraph justifying the estimated budgets, durations, and patient numbers for Phase II and III PDAC trials in Table 2. Cite multiple authoritative sources (e.g., reports from Tufts Center for the Study of Drug Development, BIO, or academic publications on trial costs) to triangulate a credible range.} \\

\textbf{C. Investment Thesis: ROI and Grant Funding Justification} \\

\parbox[t]{17.25cm}{\raggedright Instruction: Synthesize the previous analyses into a compelling investment thesis. Focus on how this specific triplicate methodology creates quantifiable value and serves as a prudent use of grant funds.} \\

\end{tabular}
\vspace{-0.1cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S59.REP.03.P45}
\bottomrule
\label{PromptFAIII}
\end{table}
\end{minipage}



\newpage

\begin{minipage}{\textwidth}
\vspace{-0.5cm}
\renewcommand{\arraystretch}{1.61}
\setlength{\tabcolsep}{0pt}
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Financial Assessment: Prompt 45 (IV/IV)} \\
\vspace{0.055cm}
\midrule
\raggedright
\fontsize{9.5pt}{10.75pt}\selectfont

\textbf{Table 3: Grant Funding Justification Framework} \\
C1: Value Driver \& Justification\\
C2: Key Supporting Finding from Simulation\\
C3: Quantifiable Financial Impact / Startup Value\\
C4: Source of Finding\\
R1\\
\textbf{Optimizing Clinical Trial Design}\\
(Value of designing a better, more successful trial)\\
The simulation confirmed a strong benefit for the KRAS G12C subgroup (Archetype-05).\\
This justifies a biomarker-driven trial design, which increases the probability of success (PoS). An increase in PoS from 10\% to 30\% on a \$20M trial has a risk-adjusted value.\\
S57.REP.01.P43, Key Insights\\
R2\\
\textbf{Justifying the Triplicate Methodology}\\
(Value of robust, defensible evidence)\\
Cross-trial consistency scores were exceptionally high (avg. >8.5/10), and the multi-AI verification confirmed result stability.\\
This provides auditable, investment-grade evidence that reduces grantor risk. The marginal cost of the triplicate run is negligible compared to the increased confidence in the go/no-go decision.\\
S57.REP.01.P43, Table 04\\
R3\\
\textbf{Accelerating Time-to-Market}\\
(Value of speed)\\
The entire project was completed in 30 days, versus the 3-5 years required for an equivalent real-world evidence base.\\
An accelerated timeline brings potential revenue forward. The Net Present Value (NPV) of future cash flows increases significantly if they are realized 3 years earlier.\\
S58.REP.02.P44, Abstract\\
R4\\
\textbf{Informing Future R\&D} \\
(Value of learning from model limitations)\\
The model's ECOG profile mismatch was identified as a key failure in external validation.\\
This is a critical, low-cost insight that informs the next, more accurate iteration of the simulation platform, improving its predictive power and future value to the startup's pipeline.\\
S57.REP.01.P43, Table 04\\



\textbf{Sample Calculations for Section C:} \\
Instruction: Provide three distinct, investment-focused sample calculations. \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 1. \hspace{0.0025cm} \textbf{Basic ROI of De-Risking:} Calculate the ROI based on the Cost of Failure Avoidance. ROI = [ (Cost of Failed Phase II Trial - Cost of Simulation) / Cost of Simulation ] * 100\%. Use figures from previous sections.} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 2. \hspace{0.0025cm} \textbf{Net Present Value (NPV) of Acceleration:} Assume a potential drug has peak sales of \$500M, 10 years from now. Show the NPV calculation using a discount rate (e.g., 15\%). Then, re-calculate the NPV assuming the timeline is accelerated by 2 years (i.e., sales start in year 3 instead of year 5). The difference in NPV is the value of acceleration. Provide the formula: NPV = $\Sigma$ [Cash Flow / (1 + r)\textasciicircum t].} \\

\parbox[t]{17.25cm}{\raggedright \hangindent=2.9em \hangafter=1 \hspace{0.4cm} 3. \hspace{0.0025cm} \textbf{Valuation Uplift from Increased PoS:} A startup's pre-clinical asset might be valued at \$5M. Industry data suggests that a successful Phase I/II result can increase valuation to \$50M. If the simulation data increases the Probability of Success (PoS) for the Phase II trial from a baseline 10\% to 25\%, calculate the increase in the risk-adjusted asset value. Formula: $\Delta$ Value = (New PoS - Old PoS) * (Post-Phase II Valuation - Investment Cost).} \\

\textbf{Rationale for Estimates:} \\
\parbox[t]{17.25cm}{\raggedright Instruction: Justify all assumptions used in the ROI and NPV calculations. Specifically explain the choice of discount rate, the estimated cost of a failed trial, and the basis for the Probability of Success figures, citing relevant financial or industry sources.} \\

\textbf{VI. Appendices} \\

\textbf{A. Data Extraction for Financial Modeling} \\
\parbox[t]{17.25cm}{\raggedright Instruction: Create a CSV-formatted table that a financial analyst could use. Populate the first row with the 100K triplicate trial data. Leave subsequent rows as examples for comparator studies.} \\

Data\_Extraction\_CSV \\
\fontsize{8.3pt}{10pt}\selectfont StudyID,StudyType,TotalBudget\_USD\_Est,Cost\_per\_Patient\_USD\_Est,Duration\_Months,FTE\_Count\_Est,Primary\_Financial\_Value,Source\_URL \fontsize{9.5pt}{10.75pt}\selectfont \\
PDAC-SIM-001\_Triplicate,Virtual,36330,0.36,1,1,"De-risking of Arm A vs Arm D",S57.REP.01.P43 \\
Comparator\_Virtual\_01,Virtual,,,,,, \\
Comparator\_PhaseII\_01,In-Person,,,,,, \\
Comparator\_PhaseIII\_01,In-Person,,,,,, \\

"Start Meta-Analysis: S58.REP.02.P44" "End Meta-Analysis: S58.REP.02.P44" \\

"Start Triplicate Results: S57.REP.01.P43" "End Triplicate Results: S57.REP.01.P43" \\

[S58.REP.02.P44] meta-analysis \\

[S57.REP.01.P43] triplicate runs \\


\end{tabular}
\vspace{-0.4cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S59.REP.03.P45}
\bottomrule
\label{PromptFAIV}
\end{table}
\end{minipage}




\begin{minipage}{\textwidth}
\renewcommand{\arraystretch}{1.61} % Adjust row height for better readability
\setlength{\tabcolsep}{0pt} % Reduces horizontal padding inside table cells
\begin{table}[H]
\centering
\begin{tabular}{p{17.8cm}}
\toprule
\centering
\vspace{-0.55cm}
\textbf{Financial Assessment Charts: Prompt 45b} \\
\vspace{0.055cm}
\midrule 
\raggedright
\vspace{0.05cm}
\fontsize{9pt}{10.5pt}\selectfont
Based on the included Financial Assessment and Value Proposition document, create 10 data visualizations with white backgrounds using separate Python scripts. Each visualization should clearly communicate key financial metrics and comparisons from the assessment to support grant funding decisions.\\
\vspace{0.1cm}
Generate the following 10 visualizations:\\
\vspace{0.1cm}
01) Horizontal Bar Chart: Compare total project costs across 100K triplicate simulation (\$36,330), single-run virtual trial (\raisebox{0.1ex}\textasciitilde\$120,000), QSP model (\raisebox{0.1ex}\textasciitilde\$600,000), Phase II trial (\raisebox{0.1ex}\textasciitilde\$20M), and Phase III trial (\raisebox{0.1ex}\textasciitilde\$100M) using logarithmic scale to show order-of-magnitude differences\\
02) Stacked Bar Chart: Show cost breakdown of the 100K triplicate simulation between labor costs (\raisebox{0.1ex}\textasciitilde\$36,000) and AI/cloud compute costs (\raisebox{0.1ex}\textasciitilde\$330) to highlight the minimal infrastructure requirements\\
03) Timeline Comparison Chart: Display project duration in months for all five methodologies (triplicate: 1 month, single-run: 3-6 months, QSP: 6-12 months, Phase II: 24-36 months, Phase III: 48-72 months) as a horizontal timeline\\
04) Cost Per Patient Comparison: Create a bubble chart showing cost per patient on log scale (\$0.36 virtual vs \$133,000 Phase II vs \$125,000 Phase III) with bubble size representing total patient count\\
05) ROI Waterfall Chart: Illustrate the 55,000\% ROI calculation showing initial investment (\$36,330), avoided failure cost (\$20M), and net benefit as sequential steps\\
06) NPV Impact Visualization: Show the \$39M value gain from 2-year acceleration using discount curves at 15\% rate comparing \$500M at year 8 vs year 10\\
07) Probability of Success Impact: Display before/after PoS (10\% to 25\%) and corresponding asset valuation increase (\$5M to \$9.5M) as paired bar charts\\
08) Capital at Risk Comparison: Create a risk matrix plot showing capital at risk vs time-to-decision for each methodology with bubble size representing uncertainty level\\
09) Cost of Reproducibility Analysis: Show marginal cost breakdown for triplicate methodology with first run cost vs additional runs (\$220 for runs 2\&3) highlighting confidence gain per dollar spent\\
10) De-risking Value Dashboard: Create a 2x2 grid showing four key metrics - cost savings from avoiding Arm A failure (\$19.96M), burn rate reduction (\$2.36M), cost reduction percentage (99.9997\%), and ROI percentage (55,000\%) as large-font metric cards.\\
\vspace{0.05cm}
“Start Financial Assessment and Value Proposition”  “End Financial Assessment and Value Proposition”\\
\vspace{0.05cm}
\lbrack S59.REP.03.P45\rbrack \\
\end{tabular}
\vspace{-0.4cm}
\midrule
\vspace{-0.2cm}
\caption{Ref: S59b.VIS.01.P45b}
\bottomrule
\label{StandardQ}
\end{table}
\end{minipage}
















\newpage
\normalsize

%Bibliography
\bibliographystyle{unsrturl}  
\bibliography{references}  

\vspace{0.1cm}
\raggedright

\begin{minipage}{\textwidth}
\section{Acknowledgments} \normalsize 

\vspace{0.025cm}

The author would like to acknowledge OpenAI for providing access to ChatGPT, Google for providing access to Gemini, Anthropic for providing access to Claude, and xAI for providing access to Grok.

\vspace{0.1cm}

% \textbf{\large Ethical disclosures} \normalsize
\section{Ethical disclosures}

\vspace{0.025cm}
 
The author of the article declares no competing interests.

\vspace{0.1cm}

% \textbf{\large Rights and permissions} \normalsize
\section{\textbf{Rights and permissions}}

\vspace{0.025cm}

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (\href{https://creativecommons.org/licenses/by/4.0/}{CC BY 4.0}), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are properly credited, a link to the Creative Commons license is provided, and any modifications made are indicated. To view a copy of this license, visit \url{https://creativecommons.org/licenses/by/4.0/}.

\vspace{0.1cm}

% \textbf{\large About this study} \normalsize
\section{About this study}

\vspace{0.025cm}

Kawchak K. ChatGPT 100,000 Patient 24-Month In Silico Phase III 5-Arm Pancreatic Cancer Clinical Trial Triplicate. Zenodo. 2025; 10.5281/zenodo.16415815 \cite{19KawchakSimPDAC}.
\end{minipage}
\end{document}
